SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

PRNewsWire • Oct 12, 2026

Celldex's skin disease drug meets goals in two late-stage trials

Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary ​goals of two late-stage trials.

Reuters • Sep 22, 2026

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

Celldex Therapeutics NASDAQ: CLDX reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.

MarketBeat • Sep 22, 2026

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.

Benzinga • Sep 22, 2026

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Seeking Alpha • Sep 22, 2026

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema Efficacy sustained or deepened from weeks 12 to 24 Well tolerated with a favorable safety profile through 24 weeks; consistent with prior studies Treatment will continue in both trials to 52 weeks; BLA submission anticipated in 2027 Company to host webcast today at 8:00 am ET HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported positive topline results from the Company's Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.

GlobeNewsWire • Sep 22, 2026

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

Zacks Investment Research • Sep 22, 2026

Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.

GlobeNewsWire • Sep 8, 2026

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.

Zacks Investment Research • Aug 7, 2026

Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts

Celldex Therapeutics remains a "Strong Buy," driven by barzolvolimab's rapid phase 3 enrollment for chronic spontaneous urticaria [CSU] and multiple late-stage catalysts. EMBARQ-CSU 1 and 2 phase 3 trials completed enrollment six months early; pivotal data expected September/October 2026, with potential BLA filing in 2027 if endpoints are met. Company is diversifying with CDX-622, a bispecific TSLP & SCF inhibitor, showing promising safety and mechanism data in phase 1, targeting asthma and other inflammatory disorders.

Seeking Alpha • Jul 26, 2026